D'Amario Federico, De Berardinis Luca, Zanon Giacomo, Qordja Fjorela, Vitale Umberto, Gigante Antonio Pompilio
Orthopedic Unit, Humanitas San Pio X, Via Francesco Nava, 31, 20159 Milano, Italy.
Clinical Orthopedics, Department of Clinical and Molecular Sciences, School of Medicine, Università Politecnica delle Marche, Via Tronto, 10/a, 60126 Ancona, Italy.
J Clin Med. 2024 Feb 25;13(5):1303. doi: 10.3390/jcm13051303.
(1) Background: Unicompartmental knee arthroplasty (UKA) provides a viable alternative to total knee arthroplasty (TKA) in patients with isolated medial osteoarthritis (OA). From 2007 to 2021, 23% of all primary knee arthroplasties in Italy were UKAs. We retrospectively evaluated clinical outcomes and satisfaction in patients implanted with a new oxinium metal-backed fixed-bearing medial unicompartmental prosthesis at a 24-month follow-up. (2) Methods: From December 2020 to December 2021, 145 patients were treated by a single surgeon at a single institution using the hypoallergenic Journey II prosthesis. Clinical outcome measures included the Knee Society Knee Score (KSKS), Knee Society Function Score (KSFS), Oxford Knee Society (OKS) score, University of California Los Angeles Activity Score (UCLA), the Physical Component Summary (PCS), and the Mental Component Summary (MCS), and were calculated preoperatively and at 12 and 24 months. The Forgotten Joint Score-12 (FJS-12) was calculated at 12 and 24 months. Patient satisfaction was collected at 24 months. The scores were compared using the Friedman test. (3) Results: All clinical scores improved significantly from baseline to 24 months ( < 0.0001), except for the FJS-12, which from 12 to 24 months did not improve significantly ( = 0.041). Patient satisfaction was 9.32 ± 0.74 out of 10. No patient experienced complications or required revision surgery. (4) Conclusions: The Journey II unicompartmental prosthesis is a valuable treatment option for end-stage medial OA, improving knee function, providing pain relief, and ensuring high patient satisfaction at 24 months.
(1) 背景：对于孤立性内侧骨关节炎（OA）患者，单髁膝关节置换术（UKA）是全膝关节置换术（TKA）的一种可行替代方案。2007年至2021年期间，意大利所有初次膝关节置换术中23%为单髁膝关节置换术。我们对24个月随访期内植入新型氧氮化锆金属背衬固定平台内侧单髁假体的患者的临床结局和满意度进行了回顾性评估。(2) 方法：2020年12月至2021年12月期间，一名外科医生在单一机构为145例患者使用低过敏性的Journey II假体进行治疗。临床结局指标包括膝关节协会膝关节评分（KSKS）、膝关节协会功能评分（KSFS）、牛津膝关节协会（OKS）评分、加利福尼亚大学洛杉矶分校活动评分（UCLA）、躯体健康评分（PCS）和精神健康评分（MCS），并在术前以及术后12个月和24个月进行计算。在术后12个月和24个月计算遗忘关节评分-12（FJS-12）。在术后24个月收集患者满意度。使用Friedman检验比较评分。(3) 结果：从基线到24个月，所有临床评分均显著改善（<0.0001），但FJS-12除外，其从12个月到24个月未显著改善（=0.041）。患者满意度为9.32±0.74（满分10分）。无患者发生并发症或需要翻修手术。(4) 结论：Journey II单髁假体是终末期内侧OA的一种有价值治疗选择，可改善膝关节功能、缓解疼痛并确保术后24个月患者满意度高。
